DDDylan Dunn

Dylan Dunn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dylan Dunn has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    VirG-specific antibodies mediate antimicrobial functions and confer cross-protection against Shigella

    by Girmay Desalegn, Leslie Bautista, Lucy Pill-Pepe, Charlotte Abrahamson, Jose M. Lemme-Dumit, Matteo Ridelfi, Dylan Dunn, Phil Fernsten, Neeraj Kapoor, Jeff Fairman, et al.

  • Open Access

    A broad spectrum Shigella vaccine based on VirG53–353 multiepitope region produced in a cell-free system

    by Girmay Desalegn, Charlotte Abrahamson, K. Ross Turbyfill, Lucy Pill-Pepe, Leslie Bautista, Chitradevi S. Tamilselvi, Dylan Dunn, Neeraj Kapoor, Barbara Sullinger, Matheo Herrera, et al.

    Dysentery caused by Shigella species remains a major health threat to children in low- and middle-income countries. There is no vaccine available. The most advanced candidates, i.e., O-polysaccharide (OPS)-based conjugates, have limited coverage—only against the immunizing serotype. Vaccines based on Shigella conserved proteins are sought for their simplicity and capacity to prevent disease caused by multiple serotypes. We previously reported the broad protective capacity of VirGα, a conserved surface-exposed domain of Shigella virulence factor. Seeking to refine the vaccine antigenic target and achieve scalable manufacturing compatible with Good Manufacturing Practices, we mapped linear B-cell epitopes spanning the entire VirG protein sequence by probing the immune reactivity of 10-mer peptides (overlapping 4–8 aa) with sera from Shigella-infected rhesus monkeys. The surface-exposed VirG53–353 subregion of the passenger α-domain demonstrated the highest and strongest immunoreactivity. VirG53–353 was produced efficiently at a large scale (>150 mg/L) using cell-free protein synthesis. When administered to mice intramuscularly, VirG53–353 elicited robust antibody responses and conferred high levels of protection against the three most prevalent Shigella serotypes (S. flexneri 2a, 3a, and S. sonnei). VirG53–353 evoked the production of Th2-type cytokines by spleen cells from vaccinated mice. A new universal Shigella vaccine based on VirG53–353 meets the World Health Organization’s preferred product specifications. The target antigen refinement and production improvement described here will facilitate the first-in-human studies.


  • Open Access

    Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate

    by Girmay Desalegn, Chitradevi S. Tamilselvi, Jose M. Lemme-Dumit, Shannon J. Heine, Dylan Dunn, Esther Ndungo, Neeraj Kapoor, Edwin V. Oaks, Jeff Fairman, Marcela F. Pasetti

    Diarrhea caused by Shigella has been associated with high morbidity and mortality in young children worldwide. There are no licensed vaccines, and those clinically advanced have restricted coverage as they elicit serotype-specific immunity while disease is caused by multiple circulating serotypes. Our group had previously reported a close association between serum antibodies to the Shigella virulence factor VirG (or IcsA) and clinical protection in infected individuals. VirG is highly conserved among Shigella strains and appealing as a broad-spectrum vaccine candidate. In this study, we investigated the immunogenicity and protective capacity of VirG as a subunit vaccine in mice. The surface-exposed alpha (α) domain of VirG (VirGα) was produced as a recombinant protein. This region has almost identical immune reactivity to full-length VirG. Administered intramuscularly with alum, VirGα elicited robust immune responses and high protective efficacy against S. flexneri 2a and S. sonnei. Almost complete protection was afforded by VirGα given intranasally with the E. coli double mutant heat-labile toxin (dmLT). VirGα-specific antibodies recognized VirG expressed on live Shigella, and blocked Shigella adhesion and invasion to human colonic cells. These results show for the first time that VirGα is a promising cross-protective vaccine candidate to prevent Shigella infection.